Our results indicate that while CD133 aptamer-DOX conjugate alone enables effective targeting and penetration of liver cancer stem cells, the concomitant inhibition of autophagy inhibition can further potentiate the capacity of CD133 aptamer-DOX in eliminating liver cancer stem cells. Here, PROM1 is linked to liver cancer.